Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.25.

Several brokerages have issued reports on ARCT. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. Osaic Holdings Inc. raised its holdings in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at about $64,000. Intech Investment Management LLC bought a new stake in Arcturus Therapeutics in the 4th quarter valued at about $70,000. Finally, CANADA LIFE ASSURANCE Co increased its position in Arcturus Therapeutics by 65.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 4,737 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Trading Down 4.5%

ARCT stock opened at $5.53 on Thursday. The firm has a market cap of $157.18 million, a PE ratio of -1.97 and a beta of 2.37. The stock has a 50-day moving average price of $7.00 and a 200-day moving average price of $7.46. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The company had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. On average, analysts forecast that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.